N
KRON

Nuveen’s Kronos Bio KRON Stock Holding History

Nuveen’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-212,946
Closed -$311K – 3253
2023
Q1 		$311K Buy
212,946
+10,523
+5% +$20.2K ﹤0.01% 2907
2022
Q4 		$328K Sell
202,423
-18,621
-8% -$42.9K ﹤0.01% 2967
2022
Q3 		$740K Sell
221,044
-8,363
-4% -$37.7K ﹤0.01% 2859
2022
Q2 		$835K Buy
229,407
+63,064
+38% +$286K ﹤0.01% 2871
2022
Q1 		$1.3M Sell
166,343
-18,781
-10% -$160K ﹤0.01% 2698
2021
Q4 		$2.52M Buy
185,124
+2,884
+2% +$45.1K ﹤0.01% 2459
2021
Q3 		$3.82M Buy
182,240
+20,325
+13% +$437K ﹤0.01% 2354
2021
Q2 		$3.88M Buy
161,915
+108,487
+203% +$2.75M ﹤0.01% 2372
2021
Q1 		$1.56M Buy
53,428
+133
+0.2% +$3.9K ﹤0.01% 2725
2020
Q4 		$1.59M Buy
+53,295
New +$1.67M ﹤0.01% 2621

Other funds holding KRON

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PCIG
Partners Capital Investment Group Boston, Massachusetts $2.65B AUM 16.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Nuveen's KRON Position: Q2 2023 in Review

Nuveen sold out of Kronos Bio (KRON) in Q2 2023, closing a stake of 212,946 shares — an estimated $311K sold.

Nuveen first reported a position in KRON in Q4 2020 and held it in 10 quarters. The position peaked at $3.88M in Q2 2021. 80 funds tracked by Wall St. Rank hold KRON as of Q2 2023.

  • Nuveen reported no remaining Kronos Bio position as of Q2 2023 after selling out during the quarter.
  • Nuveen sold 212,946 Kronos Bio shares in Q2 2023, an estimated $311K.
  • Nuveen first reported a position in Kronos Bio in Q4 2020 and held it in 10 quarters.
  • Nuveen's Kronos Bio position peaked at $3.88M in Q2 2021.
  • 80 funds tracked by Wall St. Rank held Kronos Bio as of Q2 2023.

Based on Nuveen's 13F filing for Q2 2023, filed 14 Aug 2023.